Drug Development

Jan 18, 2018
By Pharmaceutical Technology Editors
The company is developing a pipeline of combination therapies using its patented polymer-based matrix delivery system, known as TAOS (targeted orchestrated signalling matrix).
Jan 16, 2018
By Pharmaceutical Technology Editors
The two agencies have launched a program to develop safe and effective medical products to be used by American military personnel.
Jan 16, 2018
By Pharmaceutical Technology Editors
The acquisition strengthens Charles River Laboratories’ capabilities in the oncology and immunology therapeutic areas.
Jan 12, 2018
By Pharmaceutical Technology Editors
The acquisition, valued at EUR 520 million (US$631 million), would expand Takeda’s late-stage pipeline in gastroenterology and would extend an already existing collaboration between the two companies.
Jan 11, 2018
By Pharmaceutical Technology Editors
A Takeda and Denali collaboration includes three named programs for treating Alzheimer’s disease and other neurodegenerative diseases, using Denali’s antibody transport vehicle (ATV) technology to enhance blood-brain barrier penetration.
Jan 09, 2018
By Pharmaceutical Technology Editors
The company announced 15 new collaborations focused on addressing unmet medical needs, including using artificial intelligence in the early detection of Alzheimer’s disease, saliva testing for throat cancers, and using the microbiome to treat sleep disorders.
Jan 05, 2018
By Pharmaceutical Technology Editors
The companies aim to discover and develop locked nucleic acid oligonucleotides as orally available therapies for treating inflammatory bowel diseases.
Jan 05, 2018
By Pharmaceutical Technology Editors
The companies aim to develop a potential zinc finger protein transcription factor-based gene therapy for treating Lou Gehrig’s disease.
Jan 02, 2018
Pharmaceutical Technology
Brexit-related challenges cast shadows on prospects for the European bio/pharma market in 2018, but optimism may let some sun shine through.
Jan 02, 2018
Pharmaceutical Technology
Will business decisions and drug pricing policies help or hinder science and drug approval advances in 2018?
native1_300x100
lorem ipsum